ATE409479T1 - Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd) - Google Patents

Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd)

Info

Publication number
ATE409479T1
ATE409479T1 AT04720871T AT04720871T ATE409479T1 AT E409479 T1 ATE409479 T1 AT E409479T1 AT 04720871 T AT04720871 T AT 04720871T AT 04720871 T AT04720871 T AT 04720871T AT E409479 T1 ATE409479 T1 AT E409479T1
Authority
AT
Austria
Prior art keywords
pimecrolimus
ibd
rapamycin
derivatives
treatment
Prior art date
Application number
AT04720871T
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE409479(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE409479T1 publication Critical patent/ATE409479T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT04720871T 2003-03-17 2004-03-16 Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd) ATE409479T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
ATE409479T1 true ATE409479T1 (de) 2008-10-15

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720871T ATE409479T1 (de) 2003-03-17 2004-03-16 Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd)

Country Status (25)

Country Link
US (1) US20060154952A1 (de)
EP (1) EP1608368B8 (de)
JP (1) JP2006515017A (de)
KR (1) KR100855140B1 (de)
AR (1) AR043504A1 (de)
AT (1) ATE409479T1 (de)
AU (1) AU2004222563B2 (de)
BR (1) BRPI0408423A (de)
CA (2) CA2633287A1 (de)
CL (1) CL2004000535A1 (de)
DE (1) DE602004016830D1 (de)
EC (1) ECSP056006A (de)
ES (1) ES2315648T3 (de)
HR (1) HRP20050800A2 (de)
IS (1) IS8028A (de)
MA (1) MA27671A1 (de)
MX (1) MXPA05009934A (de)
MY (1) MY137868A (de)
NO (1) NO20054778L (de)
PE (1) PE20050313A1 (de)
PL (1) PL1608368T3 (de)
PT (1) PT1608368E (de)
TN (1) TNSN05197A1 (de)
TW (2) TW200503703A (de)
WO (1) WO2004082681A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 mTOR 억제제의 용도
EP2278966B1 (de) * 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3125875T3 (da) * 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク. mTOR阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1208847B8 (de) * 1996-07-30 2007-02-14 Novartis AG Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
DE10393059D2 (de) * 2002-05-09 2005-05-04 Hemoteq Gmbh Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen

Also Published As

Publication number Publication date
EP1608368A1 (de) 2005-12-28
NO20054778L (no) 2005-12-19
CA2517671A1 (en) 2004-09-30
ES2315648T3 (es) 2009-04-01
JP2006515017A (ja) 2006-05-18
MY137868A (en) 2009-03-31
AR043504A1 (es) 2005-08-03
HK1086743A1 (en) 2006-09-29
MXPA05009934A (es) 2006-03-21
EP1608368B8 (de) 2009-06-10
PT1608368E (pt) 2009-01-27
DE602004016830D1 (de) 2008-11-13
TNSN05197A1 (en) 2007-06-11
NO20054778D0 (no) 2005-10-17
WO2004082681B1 (en) 2004-11-25
KR20050110023A (ko) 2005-11-22
WO2004082681A1 (en) 2004-09-30
PL1608368T3 (pl) 2009-03-31
BRPI0408423A (pt) 2006-03-21
AU2004222563A1 (en) 2004-09-30
TW200503703A (en) 2005-02-01
HRP20050800A2 (en) 2006-11-30
ECSP056006A (es) 2006-01-27
EP1608368B1 (de) 2008-10-01
IS8028A (is) 2005-09-15
KR100855140B1 (ko) 2008-08-28
CL2004000535A1 (es) 2005-01-14
AU2004222563B2 (en) 2006-11-02
CA2633287A1 (en) 2004-09-30
TW200835484A (en) 2008-09-01
MA27671A1 (fr) 2005-12-01
PE20050313A1 (es) 2005-06-14
US20060154952A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
DE60317918D1 (de) Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
DE60118571D1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
EP1883709A4 (de) Menschliche mikro-rnas und verfahren zur hemmung davon
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
EP1690550A4 (de) Therapeutisches mittel gegen mesotheliom
EP1633362A4 (de) Verbindungen, verfahren und pharmazeutische zusammensetzungen zur hemmung von parp
ATE409479T1 (de) Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd)
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
IL172311A0 (en) Compositions and methods for treatment of disease with acetylated disaccharides
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60307766D1 (de) Gewürzmittel und Verfahren zu seiner Herstellung
SK4326U (sk) Farmaceutická kompozícia s predĺženým uvoľňovaním
DE602005005456D1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
EP1685855A4 (de) Deodorant und deodorisierender artikel
DE60202603D1 (de) 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, verfahren zur isolation aus pterocarpus marsupium und pharmazeutische zusammensetzung zur behandlung von diabetes
EP1626711A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
NO20054535D0 (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
FR2901273B1 (fr) Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
EP1734116A4 (de) Thrombinderivate und diese enthaltende medizinische zusammensetzung
EP1946007A4 (de) Androsteron-derivate und verwendungsverfahren dafür
DE602004011275D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608368

Country of ref document: EP

REN Ceased due to non-payment of the annual fee